Physician profile
Kent E Willyard
NPI 1023009214
$4,670.15
in general payments reported to CMS, 2019-2025
36 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $743 · 2021: $579 · 2022: $503 · 2023: $555 · 2024: $767 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $731.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $508.49 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $487.65 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $478.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $347.32 | 2019-2025 | |
| Amgen INC. | $206.68 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $187.86 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $187.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.72 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $139.47 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $137.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.26 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $90.87 | 2023-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $76.33 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $75.55 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $73.26 | 2021 | |
| Merck Sharp & Dohme LLC | $71.97 | 2019-2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.24 | 2024-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $58.40 | 2019-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $55.59 | 2019-2022 | |
| Amarin Pharma, INC. | $43.89 | 2019-2021 | |
| Axsome Therapeutics, INC. | $37.56 | 2025 | Auvelity |
| Allergan, INC. | $33.61 | 2019-2020 | |
| Gilead Sciences, INC. | $33.50 | 2022 | |
| Corium, LLC | $31.28 | 2023 | Adlarity |
| Actelion Pharmaceuticals US, INC. | $30.60 | 2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $30.56 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $29.63 | 2019-2020 | |
| Inari Medical, INC. | $25.31 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $18.96 | 2024 | Impella |
| Inspire Medical Systems, INC. | $16.76 | 2024 | Inspire |
| Optinose US, INC. | $15.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.55 | 2019 | |
| Sanofi Pasteur INC. | $14.41 | 2019 | |
| Shire North American Group INC | $13.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Willyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.